Valneva Announces Strong One-Year Phase 3 Results for IXCHIQ®, Its Single-Dose Chikungunya Vaccine in Adolescents

 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced additional positive Phase 3 results in adolescents for it...

January 21, 2025 | Tuesday | News
Concept Medical Announces Successful Completion of Patient Enrollment in Landmark SirPAD Trial for Peripheral Arterial Disease Treatment

CMI, a global leader in innovative drug delivery technologies for vascular procedures, is proud to announce that patient enrollment in the SirPAD trial has...

January 21, 2025 | Tuesday | News
Novo Nordisk Announces Positive Results from STEP UP Phase 3b Trial for Semaglutide 7.2 mg in Obesity Treatment

Novo Nordisk  announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial i...

January 20, 2025 | Monday | News
MediBeacon's TGFR System Receives FDA Approval for Kidney Function Assessment

MediBeacon Inc. today announced the U.S. Food and Drug Administration (FDA) has approved the MediBeacon® TGFR for the assessment of kidney fu...

January 20, 2025 | Monday | News
IMPACT Therapeutics' Senaparib Capsules Receive NMPA Approval for Maintenance Treatment of Advanced Ovarian Cancer in China

 IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company focusing on the discovery and development of targeted anti-cancer therapeutics based on s...

January 20, 2025 | Monday | News
Fermion and Simcere Partner to Advance Innovative SSTR4 Agonist for Pain Management in Greater China

Guangzhou Fermion Technology Co., Ltd. and Simcere Pharmaceutical Group Limited (HKEX: 2096) have announced a partnership to develop a clinical-stage pain ...

January 20, 2025 | Monday | News
OS Therapies Announces Positive Phase 2b Results for OST-HER2 in Preventing Recurrence of Lung Metastatic Osteosarcoma

OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, ...

January 17, 2025 | Friday | News
Silexion Therapeutics Reveals Synergistic Efficacy of SIL-204 in Combination with Chemotherapy for Pancreatic Cancer

Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNA...

January 17, 2025 | Friday | News
Solid Biosciences Advances Toward Transformative Genetic Medicines with Expanded Pipeline and New Clinical Milestones

Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines fo...

January 17, 2025 | Friday | News
Eli Lilly Secures FDA Approval for Omvoh® to Treat Moderately to Severely Active Crohn’s Disease

 Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for...

January 16, 2025 | Thursday | News
Incyte and Syndax Announce FDA Approval of Niktimvo™ for Chronic GVHD Treatment

 Incyte (Nasdaq:INCY) and Syndax Pharmaceuticals (Nasdaq:SNDX) announced that the U.S. Food and Drug Administration (FDA) has approved Niktimvo™...

January 16, 2025 | Thursday | News
Innovent Biologics’ IBI343 Receives Breakthrough Therapy Designation for Advanced Pancreatic Cancer in China

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...

January 16, 2025 | Thursday | News
Acadia Pharmaceuticals Submits Marketing Authorization Application for Trofinetide in the EU for Rett Syndrome Treatment

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced that the company has submitted a Marketing Authorization Application (MAA) to the European M...

January 15, 2025 | Wednesday | News
Libtayo® Demonstrates Significant Improvement in Disease-Free Survival for High-Risk Cutaneous Squamous Cell Carcinoma in Phase 3 C-POST Trial

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced positive results from the Phase 3 C-POST trial, which demonstrated that adjuvant treatment wi...

January 14, 2025 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close